TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20485978

Group type: EXPERIMENTAL
Intervention: Warming group (circulating-water mattress at 37 degrees centigrade)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no warming)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warming group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17682105

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 15930528

Group type: EXPERIMENTAL
Intervention: rhBMP-2/ACS
Number of subjects: 131

Group type: COMPARATOR
Intervention: autograft
Number of subjects: 131
Study: 12107606

Group type: EXPERIMENTAL
Intervention: 100 microg BDP as two inhalations from 50‐microg/actuation strength
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 microg BDP as one inhalation from 100‐microg/actuation strength
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 microg BDP as eight inhalations from the 50‐microg/actuation strength
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 microg BDP as four inhalations from the 100‐microg/actuation strength
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50‐microg/actuation strength
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100‐microg/actuation strength
Number of subjects: 30
Study: 10191374

Group type: EXPERIMENTAL
Intervention: FHL and FDL transfer to the os calcis (group II)
Number of subjects: 55

Group type: COMPARATOR
Intervention: SPLATT, Achilles tendon lengthening, and toe flexor release (group I)
Number of subjects: 55
Study: 8703667

Group type: EXPERIMENTAL
Intervention: HN-65021 (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HN-65021 (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HN-65021 (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1881694

Group type: EXPERIMENTAL
Intervention: Cefatrizine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 40
Study: 7044464

Group type: EXPERIMENTAL
Intervention: Subcuticular Dexon sutures
Number of subjects: 104

Group type: COMPARATOR
Intervention: Interrupted non-absorbable skin sutures
Number of subjects: 104
Study: 30644767

Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (CBT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Psychoeducation plus relaxation training (PRT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Exposure-based cognitive behavior therapy (CBT) and Psychoeducation plus relaxation training (PRT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Youth distress ratings
Number of subjects: 71
Study: 28887116

Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Baseline predictors
Number of subjects: 181
Study: 27578839

Group type: EXPERIMENTAL
Intervention: Provisional T-stent strategy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dual stent culotte technique
Number of subjects: 200
Study: 24476484

Group type: EXPERIMENTAL
Intervention: Resistance exercise before aerobic exercise (AR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise after aerobic exercise (RA)
Number of subjects: 0
Study: 23014835

Group type: EXPERIMENTAL
Intervention: Total hip replacement (n = 43)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Internal fixation (n = 57)
Number of subjects: 100
Study: 19583078

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.75% of inspired concentration (GI n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remifentanil continuous infusion of 0.4 microg x kg(‐1) x mn(‐1) (GR n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 17109440

Group type: EXPERIMENTAL
Intervention: Traditional microscopy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Virtual microscopy
Number of subjects: 96
Study: 15172856

Group type: EXPERIMENTAL
Intervention: Simulation training on shoulder dystocia management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no specific training
Number of subjects: 0
Study: 12512790

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sham acupuncture using the Park Sham Device
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Judgements by acupuncture experts
Number of subjects: 121
Study: 9794988

Group type: EXPERIMENTAL
Intervention: Telemedicine assessment via real-time audiovisual transmission
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional in-person assessment
Number of subjects: 15
Study: 7658530

Group type: EXPERIMENTAL
Intervention: Modified Indiana pouch procedure in elderly patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (younger patients under 75 years)
Number of subjects: 25
Study: 2693996

Group type: EXPERIMENTAL
Intervention: Oxiracetam (800-mg tablets), given twice daily for 12 weeks
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo, given twice daily for 12 weeks
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 38179

Group type: EXPERIMENTAL
Intervention: sulfasalazine and prednisone
Number of subjects: 89

Group type: COMPARATOR
Intervention: prednisone and placebo
Number of subjects: 89
Study: 31541242

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 449
Study: 30659024

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg orally, once daily)
Number of subjects: 556

Group type: COMPARATOR
Intervention: SoC EGFR-TKI (gefitinib 250 mg or erlotinib 150 mg, orally, once daily)
Number of subjects: 556
Study: 28753958

Group type: EXPERIMENTAL
Intervention: MNP+Fe (12.5 mg iron)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MNP-Fe (no iron)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CONTROL (placebo)
Number of subjects: 33
Study: 26444853

Group type: EXPERIMENTAL
Intervention: Facemask ventilation after neuromuscular blockade (NMB)
Number of subjects: 210
Study: 24146101

Group type: EXPERIMENTAL
Intervention: Transnasal EGD (TN-EGD)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Transoral EGD (TO-EGD)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Both procedures (TN-EGD and TO-EGD)
Number of subjects: 301
Study: 22344561

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU) administered postprandially after lunch
Number of subjects: 2

Group type: COMPARATOR
Intervention: Intranasal insulin (160 IU) administered in the fasted state
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (vehicle) administered postprandially after lunch
Number of subjects: 2
Study: 19144677

Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan, fluorouracil, and leucovorin (IFL)
Number of subjects: 230
Study: 17589693

Group type: EXPERIMENTAL
Intervention: 1M tacrolimus (FK 506)
Number of subjects: 14
Study: 15212189

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous 5-isosorbide mononitrate (5-ISMN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Both ISDN and 5-ISMN
Number of subjects: 25
Study: 11467638

Group type: EXPERIMENTAL
Intervention: IL-10 (8 microg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9743398

Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: bupivacaine with sufentanil 0.5 microg/ml
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: bupivacaine with sufentanil 1 microg/ml
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: bupivacaine with sufentanil 1.5 microg/ml
Number of subjects: 147
Study: 7915040

Group type: EXPERIMENTAL
Intervention: Listening to their own audiotaped voice describing anxiogenic thoughts (exposure)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reading neutral prose or poetry (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exposure only involved anxiogenic thoughts (clinical audit)
Number of subjects: 12
Study: 3200595

Group type: EXPERIMENTAL
Intervention: Standard instructions plus a pain warning (relevant anxiety condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard instructions plus a warning about a stressful interview (irrelevant anxiety condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard instructions (control group)
Number of subjects: 0
Study: 30965213

Group type: EXPERIMENTAL
Intervention: Prophylactic amoxicillin/clavulanic acid from day 29 after the start of treatment until 14 days after completion of chemoradiotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care without prophylaxis
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Prophylactic amoxicillin/clavulanic acid
Number of subjects: 106
Study: 28241185

Group type: EXPERIMENTAL
Intervention: Maintenance intervention delivered primarily by telephone, addressing satisfaction with outcomes, relapse-prevention planning, self-monitoring, and social support.
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care with no contact except for study measurements.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Maintenance intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study: 24916838

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) insulin (duration 48 h)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Subcutaneous (SQ) insulin
Number of subjects: 65
Study: 22962026

Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 90
Study: 20970238

Group type: EXPERIMENTAL
Intervention: Implementation of the Ten Group Classification System (TGCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinuation of TGCS interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline period (before TGCS implementation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asphyxia rate
Number of subjects: 0
Study: 18425015

Group type: EXPERIMENTAL
Intervention: Preoperative ability to walk
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pathological vertebral compression fracture at presentation
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (for patients unable to walk at surgery)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Symptoms present for less than 48 hours
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 78
Study: 16511728

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14662277

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 440

Group type: COMPARATOR
Intervention: Nonreamed intramedullary nailing
Number of subjects: 440
Study: 10710067

Group type: EXPERIMENTAL
Intervention: Elemental Diet (ED)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Polymeric Diet (PD)
Number of subjects: 21
Study: 9221009

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry analysis of lymphocytic infiltrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Immunophenotypic analysis of B and T lymphocytes
Number of subjects: 10
Study: 8241527

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg nocte)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg nocte)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine and Ebrotidine (both treatments)
Number of subjects: 20
Study: 3531860

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (1 X 10(6) IU) injected into warts three times weekly for three weeks
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo injected into warts three times weekly for three weeks
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 29775491

Group type: EXPERIMENTAL
Intervention: Home care via a mobile app (in addition to routine care)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Routine discharge care
Number of subjects: 203
Study: 26043186

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin 200 mg once daily
Number of subjects: 24
Study: 24299929

Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 g
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 22261740

Group type: EXPERIMENTAL
Intervention: Home Telehealth monitoring with a pendant alarm (up to 12 or 24 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (participants with a pendant alarm not from the study service provider or assessed as not needing a pendant alarm)
Number of subjects: 43
Study: 20042439

Group type: EXPERIMENTAL
Intervention: 30 minutes of prewarming with a carbon fiber total body cover at 42 degrees C
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 30 minutes of preoperative forced-air warming at 42 degrees C
Number of subjects: 27

Group type: COMPARATOR
Intervention: No prewarming (control group)
Number of subjects: 27
Study: 18339977

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus insulin lispro
Number of subjects: 56

Group type: COMPARATOR
Intervention: NPH insulin plus unmodified human insulin
Number of subjects: 56
Study: 16492297

Group type: EXPERIMENTAL
Intervention: Pacemaker with sleep rate (SR) function ON
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pacemaker with sleep rate (SR) function OFF
Number of subjects: 22
Study: 13679741

Group type: EXPERIMENTAL
Intervention: Arthroscopic free patellar tendon-bone autograft reconstruction of the anterior cruciate ligament (Group 1, 50 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Arthroscopic free patellar tendon-bone autograft reconstruction with lateral extra-articular plasty using the quadriceps tendon (Group 2, 50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 100
Study: 10856869

Group type: EXPERIMENTAL
Intervention: CABG with CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: CABG without CPB
Number of subjects: 30
Study: 9127850

Group type: EXPERIMENTAL
Intervention: Tibial tubercle elevation
Number of subjects: 15
Study: 1555991

Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia with radiation therapy (5000‐5040 cGy at 180‐200 cGy per fraction, hyperthermia delivered 30‐60 minutes after radiation for 60 minutes)
Number of subjects: 45

Group type: COMPARATOR
Intervention: One hyperthermia treatment per week for a total of five treatments
Number of subjects: 45

Group type: COMPARATOR
Intervention: Two hyperthermia treatments per week for a total of ten treatments
Number of subjects: 45
Study: 4003284

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) nifedipine (0.1, 0.2 and 0.4 microgram/kg/min over 10 minutes each)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chronic oral nifedipine (60 mg/day) in combination with atenolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Atenolol (100 to 200 mg/day)
Number of subjects: 9
Study: 30921737

Group type: EXPERIMENTAL
Intervention: Enriched CO2 (800 ± 40 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambient CO2 (400 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enriched CO2 (800 ± 40 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambient CO2 (400 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Number of subjects: 0
Study: 28829665

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 64
Study: 26251926

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 27
Study: 24215850

Group type: EXPERIMENTAL
Intervention: 400 mcg buccal misoprostol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 22372394

Group type: EXPERIMENTAL
Intervention: Nurse-led hepatitis programs of different intensity
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Older age (≥40), having a partner, and chronic homelessness
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Younger homeless persons and homeless males at risk for HBV
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Strategies to achieve HBV vaccination completion rates
Number of subjects: 297
Study: 19427257

Group type: EXPERIMENTAL
Intervention: Rubber pillow
Number of subjects: 106

Group type: COMPARATOR
Intervention: Subjects' own pillow
Number of subjects: 106

Group type: COMPARATOR
Intervention: Foam contour pillow
Number of subjects: 106

Group type: COMPARATOR
Intervention: Feather pillows
Number of subjects: 106
Study: 17982603

Group type: EXPERIMENTAL
Intervention: 6 g of table sugar (Kandisin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Artificial sweetener
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (sweetener free)
Number of subjects: 16
Study: 15077099

Group type: EXPERIMENTAL
Intervention: Early administration of reduced-dose reteplase and abciximab combination therapy
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Abciximab alone followed by PCI
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Abciximab alone administered just before PCI
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Facilitated PCI treatments (reteplase/abciximab combination therapy or abciximab alone)
Number of subjects: 3000
Study: 11707788

Group type: EXPERIMENTAL
Intervention: 1 microg/kg clonidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ketamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 45
Study: 9566121

Group type: EXPERIMENTAL
Intervention: Closed-circuit technology for testimony
Number of subjects: 2

Group type: COMPARATOR
Intervention: Live testimony in open court
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Closed-circuit technology
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Jurors' impressions based on perceived confidence and consistency
Number of subjects: 2
Study: 7914235

Group type: EXPERIMENTAL
Intervention: Inactivated IFN alpha (i-IFN alpha) with immunomodulator P40 and HIV-1 antigens (groups B and C)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Inactivated IFN alpha (i-IFN alpha) without HIV-1 antigens (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (group D)
Number of subjects: 22
Study: 3202097

Group type: EXPERIMENTAL
Intervention: Oral glucose coadministration with calcium at 222 mmol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral glucose coadministration with calcium at 0 mmol (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral glucose coadministration with calcium at 56 mmol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral glucose coadministration with calcium at 444 mmol
Number of subjects: 10
Study: 31708060

Group type: EXPERIMENTAL
Intervention: Interactive Intervention (II)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Enhanced Educational (EE) materials
Number of subjects: 507
Study: 28359280

Group type: EXPERIMENTAL
Intervention: Alcohol-free mouthrinse containing essential oils (Listerine Zero)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alcohol-based essential oils mouthrinse (EO+)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.20% chlorhexidine mouthrinse (CHX)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo solution (saline)
Number of subjects: 21
Study: 25185099

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1144
Study: 24297189

Group type: EXPERIMENTAL
Intervention: Combination therapy with pegylated interferon‐α2a (135 µg weekly) plus ribavirin (200 mg daily)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pegylated interferon‐α2a (135 µg weekly) monotherapy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Combination therapy with pegylated interferon‐α2a plus ribavirin
Number of subjects: 205

Group type: COMPARATOR
Intervention: Pegylated interferon‐α2a monotherapy
Number of subjects: 205
Study: 21600688

Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH) 37.5 IU
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH) 75 IU
Number of subjects: 187

Group type: COMPARATOR
Intervention: recombinant human follicle‐stimulating hormone (rhFSH) alone
Number of subjects: 187
Study: 18841382

Group type: EXPERIMENTAL
Intervention: Appendicitis-score group
Number of subjects: 126

Group type: COMPARATOR
Intervention: No-score group
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study: 16764872

Group type: EXPERIMENTAL
Intervention: Medical treatment of miscarriage with 200 mg of mifepristone and 0.8 mg of misoprostol 1‐3 days after the event
Number of subjects: 98

Group type: COMPARATOR
Intervention: Surgical uterine evacuation
Number of subjects: 98
Study: 14754942

Group type: EXPERIMENTAL
Intervention: Pediatric CI therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 18
Study: 11751485

Group type: EXPERIMENTAL
Intervention: Doxorubicin 80 mg/m(2) as i.v. bolus followed by paclitaxel 200 mg/m(2) as a 24-h infusion and then cyclophosphamide 3.0 g/m(2) as a 1-h infusion (arm A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Concurrent paclitaxel and cyclophosphamide at the same doses (arm B)
Number of subjects: 42
Study: 9403288

Group type: EXPERIMENTAL
Intervention: Voglibose 5 mg t.i.d.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10779290

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 microg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 microg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 30 mg/day
Number of subjects: 39